From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer’s Disease
Current Issues in Molecular Biology · 22.07.2025 · 47 (8) · 580
DOI: 10.3390/cimb47080580 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 22.07.2025. Verfasst von Luisa Agnello und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences, and Adva…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 189 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder and represents a major public health challenge. With increasing life expectancy, the incidence of AD has also increased, highlighting the need for early diagnosis and improved monitoring. Traditionally, diagnosis has relied on clinical symptoms and neuroimaging; however, the introduction of biomarkers has revolutionized disease assessment. Traditional biomarkers, including the Aβ42/Aβ40 ratio, phosphorylated tau (p-Tau181, p-Tau217, and p-Tau231), total tau (t-tau), and neurofilament light chain (NfL), are fundamental for staging AD progression. Updated guidelines introduced the ATX(N) model, which extends biomarker classification to include additional promising biomarkers, such as SNAP-25, YKL-40, GAP-43, VILIP-1, progranulin (PGRN), TREM2, IGF-1, hFABP, MCP-1, TDP-43, and BDNF. Recent advancements have allowed for the detection of these biomarkers not only in CSF but also in plasma and neuron-derived exosomes, offering less invasive and more accessible diagnostic options. This review explores established and emerging biomarkers and emphasizes their roles in early diagnosis, patient stratification, and precision medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, Department of Biomedicine, Neurosciences, and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy.
- Department of Laboratory Medicine, University Hospital "Paolo Giaccone", 90127 Palermo, Italy.
- Department of Health Promotion, Mother and Childcare, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.
- Forensic Medicine Unit, Department of Health Promotion, Mother and Childcare, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy.
ORCID-Profile: Mauro Midiri, Concetta Scazzone, Marcello Ciaccio
Zitieren
APA
Agnello, L., Gambino, C. M., Ciaccio, A. M., Cacciabaudo, F., Massa, D., Masucci, A., Tamburello, M., Vassallo, R., Midiri, M., Scazzone, C., & Ciaccio, M. (2025). From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer’s Disease. Current Issues in Molecular Biology, 47(8), 580. https://doi.org/10.3390/cimb47080580
Vancouver
Agnello L, Gambino CM, Ciaccio AM, Cacciabaudo F, Massa D, Masucci A, et al. From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer’s Disease. Current Issues in Molecular Biology. 2025;47(8):580. doi:10.3390/cimb47080580
BibTeX
@article{Agnello2025,
author = {Agnello, Luisa and Gambino, Caterina Maria and Ciaccio, Anna Maria and Cacciabaudo, Francesco and Massa, Davide and Masucci, Anna and Tamburello, Martina and Vassallo, Roberta and Midiri, Mauro and Scazzone, Concetta and Ciaccio, Marcello},
title = {From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer’s Disease},
journal = {Current Issues in Molecular Biology},
year = {2025},
volume = {47},
number = {8},
pages = {580},
doi = {10.3390/cimb47080580}
}
EUVIMED